Researchers have developed a tool to not only model the underlying disease mechanisms of glaucoma, but also to help discover and test new pharmacological strategies to combat the neurodegeneration that occurs in patients with glaucoma.
Investigators designed a method that allowed them to take patient-derived induced pluripotent stem cells and turn them into retinal ganglion cells, which are lost as glaucoma progresses.
"Our ability to direct the differentiation of human induced pluripotent stem cells to functional retinal ganglion cells allows for many new and exciting prospects for personalized medicine," said Dr. Jason Meyer, co-author of the STEM CELLS study.
Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content. The Company's website can be accessed at http://www.